Cevimeline

Drug Profile

Cevimeline

Alternative Names: AF 102B; Cevimeline hydrochloride; Evoxac; FKS 508; Saligren; SND 5088; SNI 2011; SNK 508

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Israel Institute for Biological Research
  • Developer Daiichi Sankyo Company; Nippon Kayaku; SnowBrand Pharmaceuticals
  • Class Quinuclidines; Small molecules; Thiophenes
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Xerostomia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Oct 2012 Authorised generic equivalent available in USA
  • 27 Aug 2007 No development reported - Clinical-Phase-Unknown for Dry eyes in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top